ENDOLOGIX, INC. (NASDAQ:ELGX) Files An 8-K Other EventsItem 8.01 Other Events.
On October 6, 2017, Endologix, Inc.(the “Company”) issued a press release announcing that it received Investigational Device Exemption approval from theUnited States Food and Drug Administrationto commence a confirmatory clinical study to evaluate the safety and effectiveness of the Nellix® EndoVascular Aneurysm Sealing System for the endovascular repair of infrarenal abdominal aortic aneurysms. A copy of the press release is attached hereto as Exhibit99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit Number |
Description |
|
Press Release dated October 6, 2017. |
ENDOLOGIX INC /DE/ ExhibitEX-99.1 2 ex991pressrelease-nellixco.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 INVESTOR CONTACT: Endologix,…To view the full exhibit click here
About ENDOLOGIX, INC. (NASDAQ:ELGX)
Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). Its EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.
